Journal of Cancer Research and Treatment
ISSN (Print): 2374-1996 ISSN (Online): 2374-2003 Website: Editor-in-chief: Jean Rommelaere
Open Access
Journal Browser
Journal of Cancer Research and Treatment. 2014, 2(2), 41-43
DOI: 10.12691/jcrt-2-2-3
Open AccessEditorial

Relationship between Cancer and Cytokines

Ahmed M Kabel1, 2,

1Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia

2Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta, Egypt

Pub. Date: October 10, 2014

Cite this paper:
Ahmed M Kabel. Relationship between Cancer and Cytokines. Journal of Cancer Research and Treatment. 2014; 2(2):41-43. doi: 10.12691/jcrt-2-2-3


Cancer is a group of various diseases that involve unregulated cell growth. Inflammation plays an important role in the pathogenesis of cancer. Inflammatory cytokines produced by tumor cells or inflammatory cells in the tumor microenvironment can promote tumor cell survival through the induction of genes encoding nuclear factor-kB–dependent antiapoptotic molecules. Trials with therapies that act on cytokines may represent a new hope for patients with cancer.

cytokines pathogenesis cancer

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Arnott CH, , , , , (2004). Expression of both TNF-α receptor subtypes is essential for optimal skin tumour development. Oncogene, Vol. 23, pp. 1902-1910.
[2]  Benchetrit F, , , , , , , , , (2002). Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood, Vol. 99, pp. 2114-2121.
[3]  Cho ML, , , , , , , , , , , , , , (2006). STAT3 and NF-kB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol, Vol. 176, pp. 5652-5661.
[4]  Cozen W, , , , , , et al. (2004). IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. Blood, Vol. 103, pp. 3216-3221.
[5]  De Visser KE, Eichten A, Coussens LM (2006). Paradoxical roles of the immune system during cancer development. Nat Rev Cancer, Vol. 6, pp. 24-37.
[6]  Fox JG, Wang TC (2007). Inflammation, atrophy and gastric cancer. J Clin Invest, Vol. 117, pp. 60-69.
[7]  Hao JS, Shan BE (2006). Immune enhancement and anti-tumour activity of IL-23. Cancer Immunol Immunother, Vol. 55, pp. 1426-1431.
[8]  Haura EB, Turkson J, Jove R (2005). Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol, Vol. 2, pp. 315-324.
[9]  Hussain SP, Hofseth LJ, Harris CC (2003). Radical causes of cancer. Nat Rev Cancer, Vol. 3: 276-285.
[10]  Kabel AM (2014). Effect of Combination between Methotrexate and Histone Deacetylase Inhibitors on Transplantable Tumor Model. Am J Med Studies, Vol. 2, No. 1, pp. 12-18.
[11]  Kabel AM, Abdel-Rahman MN, El-Sisi Ael-D, Haleem MS, Ezzat NM, El Rashidy MA (2013). Eur J Pharmacol, Vol. 713, No. 1-3, pp. 47-53.
[12]  Karin M (2006). Nuclear factor-kB in cancer development and progression. Nature, Vol. 441, pp. 431-436.
[13]  Kim R, Emi M, Tanabe K, Arihiro K (2006). Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res, Vol. 66, pp. 5527-5536.
[14]  Kitakata H, , , , , (2002). Essential roles of tumor necrosis factor receptor p 55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res, Vol. 62, pp. 6682-6687.
[15]  Langowski JL, , , , , , et al. (2006). IL-23 promotes tumour incidence and growth. Nature, Vol. 442, pp. 461-465.
[16]  Le Blanc HN, Ashkenazi A (2003). Apo2L/ TRAIL and its death and decoy receptors. Cell Death Differ, Vol. 10, pp. 66-75.
[17]  Lin WW, Karin M (2007). A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest, Vol. 117, pp. 1175-1183.
[18]  Luo JL, Maeda S, Hsu LC, Yagita H, Karin M (2004). Inhibition of NF-kB in cancer cells converts inflammation-induced tumor growth mediated by TNF-α to TRAIL-mediated tumor regression. Cancer Cell, Vol. 6, pp. 297-305.
[19]  Luo JL, Kamata H, Karin M (2005). IKK/NF-kB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest, Vol. 115, pp. 2625-2632.
[20]  Mantovani A, Sozzani S, Locati M, Allavena P and Sica A (2002). Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol, Vol. 23, pp. 549-555.
[21]  Mocellin S, Rossi CR, Pilati P, Nitti D (2005). Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev, Vol. 16, pp. 35-53.
[22]  Pikarsky E, , , , , , et al. (2004). NF-kB functions as a tumour promoter in inflammation-associated cancer. Nature, Vol. 431, pp. 461-466.
[23]  Trinchieri G (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev, Vol. 3, pp. 133-146.
[24]  Watford WT, , , , , (2004). Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev, Vol. 202, pp. 139-156.